"Chorionic Gonadotropin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN).
| Descriptor ID |
D006063
|
| MeSH Number(s) |
D06.472.699.322.326 D06.472.699.649.367 D12.644.548.726.367 D12.776.780.400
|
| Concept/Terms |
Chorionic Gonadotropin, Human- Chorionic Gonadotropin, Human
- Gonadotropin, Human Chorionic
- Human Chorionic Gonadotropin
- HCG (Human Chorionic Gonadotropin)
|
Below are MeSH descriptors whose meaning is more general than "Chorionic Gonadotropin".
Below are MeSH descriptors whose meaning is more specific than "Chorionic Gonadotropin".
This graph shows the total number of publications written about "Chorionic Gonadotropin" by people in this website by year, and whether "Chorionic Gonadotropin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chorionic Gonadotropin" by people in Profiles.
-
The HERA (Hyper-response Risk Assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization. J Assist Reprod Genet. 2023 Nov; 40(11):2681-2695.
-
Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology. Brain Tumor Pathol. 2023 Apr; 40(2):124-132.
-
Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial. JAMA. 2021 08 03; 326(5):390-400.
-
ß-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue. Carcinogenesis. 2019 Nov 25; 40(11):1415-1426.
-
Optimal treatment for women with a persisting pregnancy of unknown location, a randomized controlled trial: The ACT-or-NOT trial. Contemp Clin Trials. 2018 10; 73:145-151.
-
Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstet Gynecol. 2016 Sep; 128(3):535-542.
-
In high responding patients undergoing an initial IVF cycle, elevated estradiol on the day of hCG has no effect on live birth rate. Reprod Biol Endocrinol. 2014 Nov 28; 12:119.
-
Expectant management of ectopic pregnancy. Clin Obstet Gynecol. 2012 Jun; 55(2):461-70.
-
Synthetic human chorionic gonadotropin-related oligopeptides impair early innate immune responses to Listeria monocytogenes in Mice. J Infect Dis. 2010 Apr 01; 201(7):1072-80.
-
Levels of insulin-like growth factor (IGF) binding proteins, luteinizing hormone and IGF-I receptors, and steroids in dominant follicles during the first follicular wave in cattle exhibiting regular estrous cycles. Endocrinology. 1996 Jul; 137(7):2842-50.